Archive

Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

Posted on August 6, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry -...

Read More

Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

Posted on August 6, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present...

Read More

Tiara and Reducer Featured at CSI Frankfurt 2018

Posted on July 2, 2018
in
by

NASDAQ, TSX: NVCN VANCOUVER, July 2, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ ("Tiara"), a transcatheter treatment of mitral valve disease, and the...

Read More